drugset / Trial / NCT00377273

An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses

NCT00377273

Phase 4 Completed 250 enrolled Sanofi
RandomizedSingle-groupOpen-labelTreatment

Summary

This study is being undertaken to: 1. assess the safety of fluorouracil cream for the treatment of actinic keratoses ("AKs") on other common skin surface areas (e.g., posterior scalp, ears, neck, lips, arms and hands); 2. collect additional post-treatment safety data on fluorouracil cream applied to the face (including anterior scalp, if applicable); 3. assess the incidence of recurrence of AKs on the face; and 4. assess the need for re-treatment with fluorouracil cream to the face.

Timeline

Start
2003-11
Primary completion
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject fluorouracil Small molecule 0.5 %

Indications